CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy

– Following ratification by the European Commission, Evrysdi will be available to treat all spinal muscular atrophy patients, including babies from birth – SOUTH PLAINFIELD, N.J., July 21, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.